Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The user experienced noticeable hair regrowth and increased density after 6 months on oral minoxidil and 4 months on dutasteride, along with weekly derma rolling, tretinoin, and Nizoral shampoo. They reported no side effects from the treatment.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

A user experienced hair regrowth after 6 months on finasteride, which is earlier than the usual 12-18 months observed by their dermatologist. The dermatologist noted this as an exceptionally good response.

The user has been using various hair loss treatments, including dutasteride, oral minoxidil, finasteride, RU58841, and dermarolling, but feels they may have lost hair and is considering a hair transplant. They are advised to stick to one treatment for 6-12 months to see results, as frequent changes may hinder progress.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A user is treating hair loss with 0.5mg Dutasteride three times a week, 5mg oral Minoxidil daily, and topical finasteride and minoxidil, seeing some improvement but insufficient density. They are considering increasing Dutasteride dosage and addressing high estradiol levels, while also trying to quit vaping.

A user increased their finasteride dosage from 0.5 mg to 1 mg due to ongoing hair miniaturization, despite some improvement. They are considering dutasteride and have not used minoxidil, but are cautious about potential side effects.

The user is pleased with their hair transplant results but is concerned about the vertex area. They use Minoxidil and finasteride daily and had the procedure at a clinic in Athens.

The user reports positive hair regrowth after 6 months using finasteride, minoxidil, occasional derma rolling, and weekly ketoconazole shampoo. Other users encourage the progress and share their own experiences with finasteride.

Dutasteride can significantly increase libido, more so than finasteride. Users reported higher libido when switching from finasteride to dutasteride.

User AdDazzling5710's progress using Dutasteride for hair loss, with other users providing helpful advice and support.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

A 25-year-old male is experiencing advanced hair loss and is using topical and oral minoxidil, topical finasteride, and vitamin D3, but has not seen significant regrowth. He is considering switching treatments, including oral dutasteride, topical spironolactone, and possibly a scalp biopsy to better understand his condition.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

The user experienced hair regrowth using a combination of Minoxidil, Finasteride, and RU58841, with Minoxidil used initially and the other treatments added later. The user believes the combination of Finasteride and RU58841 contributed to the regrowth, with RU sourced from MVsupplement.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

The user has been on dutasteride for 6 months, experiencing initial hair health but then shedding and brittle hair, with no improvement. They use minoxidil, ketoconazole, dutasteride, and vitamin D, and are questioning whether to continue treatment despite no results.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The user started using EssenGen 6-Plus, containing 6% minoxidil and 0.05% finasteride, along with 1% Nizoral shampoo, and reported noticeable hair growth in 7 weeks. They experienced some chest tightness but are monitoring it, and they are satisfied with the progress despite using a silicone-containing shampoo.

Dutasteride is shown to be significantly more effective than finasteride for treating male androgenic alopecia. Users discuss the difficulty of obtaining dutasteride in some countries and share personal experiences with its effectiveness and side effects.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

A user's 11-month hair loss treatment progress using 0.5mg dutasteride every other day, 50mg RU58841 in the morning, 5mg oral minoxidil, topical minoxidil at night, and microneedling with a 1.5mm needle every other week. The user's improvement was significant, going from a severe hair loss stage (NW7) to a mild/moderate stage (NW2-3).

The user shared their 6-month progress using Dutasteride .5 daily, RU 100mg once a day, and 15 mg oral Minoxidil for hair loss. They reported visible results, no side effects, and increased body hair, despite concerns from others about the high dosage and potential health risks.

The conversation discusses a 6-month hair loss treatment update using 1mg finasteride and 5% minoxidil daily. Some users apply minoxidil once or twice a day, and there's no mention of using a dermaroller or dermastamp in the treatment.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.